CN102078367B - Application of Aidi preparation in preparation of medicine for treating senile multiple organ dysfunction syndrome - Google Patents
Application of Aidi preparation in preparation of medicine for treating senile multiple organ dysfunction syndrome Download PDFInfo
- Publication number
- CN102078367B CN102078367B CN200910102893XA CN200910102893A CN102078367B CN 102078367 B CN102078367 B CN 102078367B CN 200910102893X A CN200910102893X A CN 200910102893XA CN 200910102893 A CN200910102893 A CN 200910102893A CN 102078367 B CN102078367 B CN 102078367B
- Authority
- CN
- China
- Prior art keywords
- preparation
- aidi
- medicine
- organ dysfunction
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 74
- 239000003814 drug Substances 0.000 title claims abstract description 32
- 208000010718 Multiple Organ Failure Diseases 0.000 title claims description 49
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 title claims description 47
- 238000011282 treatment Methods 0.000 claims description 46
- 241000208340 Araliaceae Species 0.000 claims description 19
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 17
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 17
- 235000008434 ginseng Nutrition 0.000 claims description 17
- 241000124079 Mylabris Species 0.000 claims description 16
- 239000007924 injection Substances 0.000 claims description 16
- 238000002347 injection Methods 0.000 claims description 16
- 239000009636 Huang Qi Substances 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 11
- 239000000284 extract Substances 0.000 claims description 10
- 210000003462 vein Anatomy 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 241000545442 Radix Species 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000375 suspending agent Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 20
- 201000010099 disease Diseases 0.000 abstract description 19
- 208000011580 syndromic disease Diseases 0.000 abstract description 6
- 230000004064 dysfunction Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 210000002216 heart Anatomy 0.000 description 13
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 11
- 108010082126 Alanine transaminase Proteins 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 9
- 210000003734 kidney Anatomy 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- 230000029058 respiratory gaseous exchange Effects 0.000 description 7
- 206010030113 Oedema Diseases 0.000 description 6
- 229920000392 Zymosan Polymers 0.000 description 6
- 210000003701 histiocyte Anatomy 0.000 description 6
- 230000008595 infiltration Effects 0.000 description 6
- 238000001764 infiltration Methods 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 206010020565 Hyperaemia Diseases 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000036285 pathological change Effects 0.000 description 5
- 231100000915 pathological change Toxicity 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000004768 organ dysfunction Effects 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 229940099472 immunoglobulin a Drugs 0.000 description 3
- 229940027941 immunoglobulin g Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000004347 intestinal mucosa Anatomy 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- 208000037157 Azotemia Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 208000028399 Critical Illness Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010053159 Organ failure Diseases 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000005086 glomerual capillary Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 210000004276 hyalin Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000008383 multiple organ dysfunction Effects 0.000 description 2
- 230000010355 oscillation Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000004876 tela submucosa Anatomy 0.000 description 2
- 241000045403 Astragalus propinquus Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241001632410 Eleutherococcus senticosus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001481669 Meloidae Species 0.000 description 1
- 241001572617 Mylabris cichorii Species 0.000 description 1
- 241001572616 Mylabris phalerata Species 0.000 description 1
- 241001474977 Palla Species 0.000 description 1
- 240000004371 Panax ginseng Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- DHZBEENLJMYSHQ-XCVPVQRUSA-N cantharidin Chemical compound C([C@@H]1O2)C[C@@H]2[C@]2(C)[C@@]1(C)C(=O)OC2=O DHZBEENLJMYSHQ-XCVPVQRUSA-N 0.000 description 1
- 229940095758 cantharidin Drugs 0.000 description 1
- 229930008397 cantharidin Natural products 0.000 description 1
- DHZBEENLJMYSHQ-UHFFFAOYSA-N cantharidine Natural products O1C2CCC1C1(C)C2(C)C(=O)OC1=O DHZBEENLJMYSHQ-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229940124645 emergency medicine Drugs 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000033065 inborn errors of immunity Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008807 pathological lesion Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- -1 pulverize Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to an application of an Aidi preparation in preparing a medicament for treating senile diseases, in particular to an application in preparing a medicament for treating senile multi-organ dysfunction syndrome.
Description
Technical field
The present invention relates to the new purposes of Chinese medicine Aidi preparation in the medicine of the senile common disease of preparation treatment, specifically relate to the purposes of Aidi preparation in the old multiple organ dysfunction syndrome's medicine of preparation treatment.
Technical background
Senile disease is meant and old and feeble diseases associated, can take place in person in middle and old age's phase, also possibly take place in the geratic period, but the geratic period is more common.Along with the progress of society, growth in the living standard, life-time dilatation, the old people is than constantly increasing, and the thing followed is that Senile disease increases.These are sick aging with old people's pathologic; The body function reduction of exempting from service is relevant; Like blood circulation diseasess such as hypertension, ischemic heart desease, heart failure; Respiratory system diseases such as pneumonia, chronic bronchitis, emphysema, hypoxemia and respiratory failure, endocrine metabolic system diseases such as diabetes, hyperlipemia, hyperuricemia, and the full syndrome (MODSE) of digestive system disease, old multi-organ function, malignant tumor etc.
Old multiple organ dysfunction syndrome (multiple organ dysfunction syndrome in the elderly; MODSE) be meant the old people the organ aging with suffer from the basis of multiple chronic disease; Excite by certain inducement; It is sequential or obstacle and depleted clinical syndrome take place simultaneously to occur 2 or 2 above organs at short notice, is the major reason of old critical illness death.MODSE is with common multiple organ dysfunction syndrome (multiple organ dysfunction syndrome; MODS) similar characteristics are arranged; But its epidemiology, pathogenic factor, pathogenesis, clinical characters and prevention treatment effect aspect all are different from general MODS.It takes place and the old people, and the patient often has multiple underlying diseases, hypoimmunity; The internal organs reserve function reduces, and morbidity back change of illness state is complicated, is prone to metabolism disorder; Therefore treatment difficulty is big; In earlier stage it is rapider to carry out the transition to SE by the organ failure, in case get into organ failure's phase, gerontal patient's mortality rate is very high.
Have survey data to show that the nineties in 20th century, China MODSE annual morbidity was 6,50/,100,000, case fatality rate 75%～100% is one of aging population main causes of death; (systemicinflammatory response syndrome, annual morbidity SIRS) is about 2,50/,100,000 to systemic inflammatory response syndrome, wherein 40% dies from MODSE in the same period U.S. population.It is thus clear that the sickness rate of MODSE and case fatality rate are all very high, be the key factor that jeopardizes the senior health and fitness.Event needs to improve the comprehensive treatment of patient's immunity.
Aidi preparation is to be primary raw material with Radix Ginseng, Mylabris, the Radix Astragali and Radix Et Caulis Acanthopanacis Senticosi, extracts the preparation that its extract with medical value is processed as effective ingredient.The effect of heat-clearing and toxic substances removing, repercussive eliminating stagnation is arranged, and wherein ad pro injection records in 20 of Ministry of Public Health ministry standards, is mainly used in the treatment of primary hepatocarcinoma, pulmonary carcinoma, rectal cancer, malignant lymphoma, gynecologic malignant tumor etc. clinically.
Applicant of the present invention is CN03117114.1, the name patent of invention that is called " treatment tumor traditional medicine Injectio and preparation method thereof " and number of patent application is that CN 200510003151.3, name are called in the patent of invention of " a kind of method for preparing of treating the Chinese medicine preparation of tumor " and disclose Aidi preparation for preparing with Radix Ginseng, Mylabris, the Radix Astragali and Radix Et Caulis Acanthopanacis Senticosi and preparation method thereof in the patent No..Though research before shows Aidi preparation and can be used to prepare the treatment tumor, regulate the medicine of various disease conditions such as immunity, does not see and utilizes the patent documentation and research report of Aidi preparation to the therapeutical effect of Senile disease aspect.The applicant is also unexpected in research subsequently to find that Aidi preparation can be used for the treatment of Senile disease, particularly has the obvious treatment effect aspect the infull syndrome of the old multi-organ function of treatment.
Summary of the invention
The purpose of this invention is to provide the purposes of a kind of Aidi preparation in preparation treatment Senile disease medicine.
Another purpose of the present invention provides the purposes of a kind of Aidi preparation in the infull syndrome medicament of the old multi-organ function of preparation treatment.
Aidi preparation of the present invention is by forming from Radix Ginseng, Mylabris, the Radix Astragali and Radix Et Caulis Acanthopanacis Senticosi.Mainly be to contain the extract that from Radix Ginseng, Mylabris, the Radix Astragali and Radix Et Caulis Acanthopanacis Senticosi, extracts as effective ingredient with medical value.According to listed as parts by weight, Aidi preparation according to the invention is to be prepared from through extraction raw material of Chinese medicine Radix Ginseng 25-100 part, Mylabris 0.5-5 part, Radix Astragali 50-200 part and Radix Et Caulis Acanthopanacis Senticosi 100-200 part.
Preferred proportioning is: Radix Ginseng 30-70 part, Mylabris 1-2 part, Radix Astragali 75-125 part, Radix Et Caulis Acanthopanacis Senticosi 125-175 part.
Most preferred proportioning is: 50 parts of Radix Ginsengs, 1.5 parts of Mylabris, 100 parts of the Radixs Astragali, 150 parts of Radix Et Caulis Acanthopanacis Senticosis.
When using, medicine of the present invention can add one or more pharmaceutically acceptable carriers as required, like diluent, filler, binding agent, excipient, disintegrating agent, surfactant, absorption enhancer and lubricant etc.
Aforesaid Aidi preparation preferably uses with the form of injection, tablet, pill, capsule, granule, Emulsion, solution or suspending agent, more preferably injection.Above-mentioned dosage form all can be according to the conventional method preparation of pharmaceutical field.
The route of administration of aforesaid Aidi preparation is oral, percutaneous, vein or intramuscular injection.
In the method for preparing of Aidi preparation of the present invention; Its effective component extracts can be that the method for CN03117114.1 is extracted according to the patent No.; Also can according to the patent No. be among the CN200510003151.3 method extract, can also extract with the method for routine.
Aidi preparation of the present invention, its effective ingredient Radix Ginseng are the dry root of Araliaceae Radix Ginseng Panax ginseng C.A.Mey., sweet in the mouth, little hardship, and tepor has strongly invigorating primordial QI, invigorating the spleen to benefit the lung, the beneficial blood that promotes the production of body fluid, calming the nerves increases the effect of intelligence; Mylabris is the dry body of Meloidae insecticide south mylabris phalerata Mylabris phalerata Pallas or yellow black mylabris cichorii Mylabris cichoriiLinnaeus, and property is hot, hot, very toxic, has that removing blood stasis is become thin, the effect of counteracting toxic substances phagedenoma; The Radix Astragali is the dry root of leguminous plant Radix Astagali Astragalus membranaceus (Fisch.) Bge.var.mongholocus (Bge.) or Radix Astragali, has the effect of invigorating QI to consolidate the body surface resistance, diuresis poison holding, evacuation of pus, expelling pus and promoting granulation; Radix Et Caulis Acanthopanacis Senticosi is dry root and rhizome or the stem of Araliaceae Radix Et Caulis Acanthopanacis Senticosi Acanthopanax senticosus (Rupr.et Maxim.) Harms, has the effect of replenishing QI to invigorate the spleen, tonifying the kidney for tranquilization.Four share have heat-clearing and toxic substances removing, the effect of repercussive eliminating stagnation.
The active component of Aidi preparation is Radix Ginseng, Mylabris, the Radix Astragali and Radix Et Caulis Acanthopanacis Senticosi, and Radix Ginseng can be used for vigour collapse card, lung spleen heart syndrome of deficiency of kidney-QI, calentura deficiency of vital energy Tianjin wound and reaches diabete yearningly; Mylabris can be used for stubborn dermatitis 、 WEIJIA lump, the dead flesh of malignant boil etc. for many years; The Radix Astragali can be used for that the deficiency of vital energy is weak, anorexia and loose stool, sinking of QI of middle-JIAO, exterior deficiency spontaneous perspiration; Radix Et Caulis Acanthopanacis Senticosi can be used for that deficiency of spleen-YANG and kidneyYANG, body void are weak, inappetence, soreness of waist and knee joint, insomnia and dreamful sleep etc.Above-mentioned four kinds of effects that medicine has invigorating the spleen and replenishing QI, promotes the production of body fluid and nourish blood can promote body growth, and the effect of antioxidation, enhance immunity is arranged.Therefore, Aidi preparation is used with Senile disease and should be had certain curative effect.The further experimental study of the applicant finds that Aidi preparation really can be used for preparing the medicine of treating Senile disease, treats the not medicine of full syndrome of old multi-organ function especially for preparation.
The specific embodiment
In order to make those of ordinary skills better understand the present invention, below come further to set forth Aidi preparation of the present invention through experimental example composition and method for preparing, and the experimentation of Aidi preparation in treatment Senile disease medicine.Need to prove: following examples are merely explaination the present invention, rather than restriction the present invention.
Embodiment 1: a kind of prescription of Aidi preparation and preparation thereof
Raw material: Radix Ginseng 500g, speckle insect destructive of the roots of seedlings 15g, Radix Astragali 1000g, Radix Et Caulis Acanthopanacis Senticosi 1500g
Method for preparing: get the Mylabris medical material, pulverize, extract 5 times with 400ml 100% alcohol heating reflux, extraction time is respectively: 2h, 1h, 0.5h, 0.5h, 0.5h; Filter, medicinal residues are subsequent use, and extracting solution transfers to pH8-9 with 4% sodium hydroxide solution, decompression recycling ethanol; Filter, thin up transfers to pH6-7 to 1000ml with 12% hydrochloric acid solution, leaves standstill; Cold preservation, centrifugal filtration, supernatant transfers to pH8-9 with 4% sodium hydroxide solution, and is subsequent use; Get the Radix Ginseng section, extract 3h with 480ml 60% alcohol heating reflux, filter, medicinal residues are subsequent use; It is 150ml that extracting solution decompression recycling ethanol, concentrated solution add water to volume, and last macroporous adsorbent resin adds 5 times of column volumes of water elution; 5 times of column volume eluting of reuse 80% ethanol are collected eluent, reclaim ethanol; Concentrate, filter, subsequent use; Get the Radix Astragali, Radix Et Caulis Acanthopanacis Senticosi medical material, merge with Radix Ginseng, Mylabris medicinal residues, add the 24960ml decocting and boil 5 times, extraction time is respectively: 3h, 2h, 1h, 0.5h, 0.5h, collecting decoction; Filter, being concentrated into volume is 1560ml, filters, and supernatant adds ethanol, makes to contain the alcohol amount and reach 60%; Transfer pH7 with 7% sodium hydroxide solution, cold preservation is filtered, and supernatant adds ethanol again; Make to contain alcohol amount and reach 60%, cold preservation is filtered, and reclaims ethanol; Add water to 1200ml, transfer pH4～5, add 0.3% active carbon boiling decoloring 40min, centrifugal filtration with 12% hydrochloric acid solution; Supernatant and Radix Ginseng, Mylabris extracting solution merge, and add the injection water to 10000ml, and regulating liquid PH value is 3, filters, and embedding, sterilization promptly get 1000 of Aidi injection preparations, and dosage is that 10ml/ props up, and every contains cantharidin (C
10H
12O
4) be 0.008～0.030mg.Quality standard meets Ministry of Public Health medicine sanitary standard regulation and Chinese Pharmacopoeia 2005 editions.
Embodiment 2 Aidi preparations are to the protective effect of old multiple organ dysfunction syndrome (MODSE) Rats Organs and Tissues
This experiment adopts the method for lumbar injection zymosan to duplicate senile rat MODSE model, observes the influence of Aidi preparation to MODSE rat plasma alanine aminotransferase (ALT), creatinine (Cr), breathing (R), heart rate (HR) and histopathology.
1, material and reagent
1.1 medicine and reagent: ad pro injection, 10ml/ props up, by the method for the invention preparation; Zymosan (Zymosan A, Sigma Company products, 2g/ bottle); Creatinine (Cr) and alanine aminotransferase (ALT) test kit, Nanjing build up bio-engineering research institute and Shanghai Rongsheng Bioisystech Co., Ltd provides lot number: 031209,3061051.
1.2 experimental animal: old male SD rat, 60, body weight 200-250g, Guiyang Medical College provides.
1.3 instrument: BIOPAC SYSTEMS (MP150 type) 16 road physiology system log (SYSLOG) appearance (U.S.); XW-80A vortex mixer (Instrument Factory, Shanghai Medical Science Univ.) and KS type electric agitator (Shenyang City's temperature detect switch (TDS) factory); Anke TDL-5-A refrigerated centrifuge (Shanghai), UV2754 spectrophotometer (Shanghai).
2, experimental technique
2.1 model preparation: get 2g zymosan A, be dissolved to 500ml with the medical sterilization paraffin liquid, higher-order of oscillation 30min, sonic oscillation 6h is prepared into 4mg/ml zymosan A suspension.Press the modeling of zymosan 16mg/kg (4ml/kg) lumbar injection.The medical sterilization paraffin liquid of capacity such as blank control group lumbar injection.
2.2 divide into groups and administration: 60 of old SD rats are divided into model group at random, and Ai Di tests low dose group, Ai Di experiment high dose group and blank group, 15 every group.Give Aidi preparation low dosage 10ml/kg and high dose 30ml/kg medicinal liquid by body weight.Before the modeling, with rat drug administration by injection 1 time, every at a distance from 12h administration 1 time again after the modeling, blank control group is given the normal saline of the capacity of grade.
2.3 sample collection and detection: respectively at after the modeling 12,24,48h, lumbar injection chloral hydrate (350mg/kg) anesthetized rat is measured rat temperature, frequency of respiration and heart rate.Abdominal aortic blood, anticoagulant heparin, centrifugal separation plasma ,-20 ℃ of refrigerators are preserved; And press the test kit explanation and survey ALT and Cr.Get lung, liver, small intestinal, heart and kidney, with 10% formalin fixed, the film-making histological examination.The organ disease grade scale is seen table 1.
Table 1 organ disease grade scale
| Grade scale | By aspect pathological changes classifications such as histiocytic arrangement, inflammatory cell infiltration degree, histiocytic degeneration, the variations of histiocyte medium vessels |
| 0 grade | Normal liver tissue |
| 1 grade | Slight inflammatory cell infiltration, the congested and expansion of slight histiocyte medium vessels |
| 2 grades | Moderate primary cellular defect companion inflammatory cell infiltration, obviously histiocyte medium vessels hyperemia, interstitial edema and focal sexual cell are downright bad |
| 3 grades | Extensive inflammatory cell infiltration, obviously histiocyte medium vessels hyperemia, interstitial edema in the histiocyte, downright bad, the atrophy of histiocyte widely |
| Statistical method | Optional 5 low-power fields of each tissue slice are judged its histological grade, average as the histological grade of this BIAO and BEN |
2.4 statistical result and processing: all data all use x ± s to represent, mean relatively adopts the t check between two groups, and mean relatively adopts the one factor analysis of variance check between many groups, and ranked data adopt x
2Check, the The data software processes.
3, result
3.1 the result that influences to MODSE rat plasma Cr and ALT content finds: model group rat plasma Cr, ALT content significantly raise (P＜0.05), and Aidi preparation is low, high dose group rat plasma Cr, and ALT content and model group significantly reduce (P＜0.05).The result sees table 2.
After table 2 modeling 12,24,48h plasma C r and ALT (x ± s)
Annotate: compare * P＜0.05 with model group; Compare Δ P＜0.05 with blank control group
3.2 the result that influences to MODSE rats breathing number of times and heart rate finds: model group rats breathing number of times significantly raise (P＜0.05); Low, high dose group rats breathing number of times of 48h Aidi preparation and model group significantly reduce (P＜0.05) after the modeling; Model group rat heart rate significantly raise (P＜0.05); Ai Di high dose group rat heart rate and model group significantly reduce (P＜0.05).The result sees table 3.
After table 3 modeling 12,24,48h frequency of respiration and heart rate (x ± s)
Annotate: compare * P＜0.05 with model group; Compare Δ P＜0.05 with blank control group
See table 4～5 3.3 respectively organize lung after the modeling as a result of Rats Organs and Tissues histopathology, small intestinal, liver, kidney device lesion degree hierarchical statistics result.
Model group: visible interstitial lung and alveolar sheet kitchen range technology edema, be filled with fibrin granule and leukocyte in the alveolar space, alveolar membrane thickens, and the alveolar hyaline membrane forms, and the little blood vessel neutrophilic granulocyte of lung gathers microthrombusis; Hepatocyte endochylema cloudy swelling, sinus hepaticus hyperemia and cell infiltration, the obvious hypertrophy of Kupffer; Glomerular capillary is hyperemia or ischemia changes, renal cells cloudy swelling, hyaline degeneration; Intestinal mucosa and Submucosa are congested, edema and chronic inflammation cellular infiltration, local mucosa hemorrhage and epitheliolysis, come off, and prolong intestinal mucosa in time and destroy or atrophy.Heart is not seen obvious pathological change.
After table 4 modeling 12,24,48h MODSE rat lungs and disorder of the small intestine variation level meansigma methods statistics
Ai Di treatment group and blank control group: the pathological change of Ai Di high dose and low dose group all obviously alleviates than model group.It is thus clear that the interstitial lung Mild edema and the congestion of blood vessel; Hepatocyte endochylema cloudy swelling and acidophilia become; Glomerular capillary is congested, ischemia, the slight cloudy swelling of renal cells, degeneration; The focal hyperemia of small intestinal mucosa and Submucosa, edema; The treatment group is heavier slightly than blank control group.Heart is not seen obvious pathological change.
After table 5 modeling 12,24,48h MODSE rat liver and nephropathy classification meansigma methods statistics
4, conclusion
The mensuration result of plasma C r shows: the model group rat is that azotemia meets the depleted rule of kidney along with the time lengthening renal function is progressively worsened by functional compensation; The basic held stationary level though Ai Di low dose group Cr raises, renal function is relatively stable have better compensatory; Progress was heavier azotemia when Ai Di high dose group Cr slowly was elevated to 48h, and reaction possibly have certain influence to kidney simultaneously but illustrative dosage controls inflammation more greatly, shows that suitable dosage has protective effect to kidney.
Plasma A LT measures the result and shows: model group rat ALT is along with time lengthening raises gradually; Though raising to some extent, Ai Di high dose and low dose group ALT do not see the deterioration sign that increases progressively in time; The results suggest Aidi preparation has the liver assist detoxifcation and the reaction that controls inflammation, and the effect of the liver protecting function is arranged.Experiment also shows the frequency of respiration, heart rate of model group rat along with time lengthening has the phenomenon of increasing progressively, and Ai Di treatment group obviously alleviates than model group.The proof Aidi preparation has certain protective role to the MODSE organ dysfunction.
Histopathology is observed and is shown that also Aidi preparation can alleviate dirty pathological lesions such as the small intestinal of MODSE rat model, lung, liver, kidney.
Multiple organ dysfunction had protective effect when above result showed Aidi preparation to MODSE; And can have the pathological change of organ-tissue and obviously alleviate effect; This experiment proves absolutely that for the treatment that Aidi preparation is applied to old multiple organ dysfunction syndrome provides certain experimental basis Aidi preparation has good curative effect and potential therapeutic value to MODSE.
Embodiment 3 Aidi preparations are to the treatment of old multiple organ dysfunction syndrome
1, case is selected: old multiple organ dysfunction syndrome (MODSE) diagnostic criteria that proposes according to Wang Shiwen (Wang Shiwen, Wang Jinda, Chen Keji, etc.Old multiple organ dysfunction syndrome (MODSE) diagnostic criteria.China's critical illness emergency medicine.2004 01 phases) screen, by stages, gerontal patient's 41 examples of clarifying a diagnosis to multiple organ dysfunction syndrome are divided into two groups at random, 22 examples are organized in treatment, male 12 examples, women 10 examples, age 65-87 year, average 71.4 years old; Matched group 19 examples, male 10 examples, women 9 examples, age 65-86 year, average 70.8 years old.The Insufficient organ number of organ 2-4 takes place, and is in 36 examples in depleted early stage.Two groups all have comparability aspect age, sex, the course of disease, the state of an illness.The each patient all suffers from 2-10 kind chronic disease, is many with respiratory system disease, cardiovascular and cerebrovascular disease wherein, is digestive tract disease secondly, and the inducement that organ dysfunction is incomplete is main with infection, is hemorrhage secondly, arrhythmia, factors such as allergy.The multiple order that organ dysfunction is incomplete is lung, the heart, kidney, digestive tract.
2, Therapeutic Method: two groups of patients' conventional therapy is identical; Treatment group vein drips ad pro injection 100ml (using with 0.9% sodium chloride or 5～10% glucose injections, 400～450ml dilution back)/day; 10 days courses of treatment, influence the medicine of immunologic function during the medication without other.
3, assay method: before and after the treatment, extracting vein blood is analyzed t lymphocyte subset crowd CD3, CD4, CD8, uses the colorimetric method for determining immunoglobulin, simultaneously the change situation of clinical symptoms, sign before and after the recording medicine.Curative effect determinate standard (each item index with in the MODSE diagnostic criteria is the basis):
It is invalid to be regarded as---treat 1 course of treatment after, each organ dysfunction index no change or deterioration;
Being regarded as effectively---the functional defect organ number of depleted early stage/SE reduces or is transferred in earlier stage depleted by SE;
Being regarded as produce effects---depleted early stage/SE transfers to normally.
Statistical procedures adopts t check and Fisher check.
4, result
4.1 table 6 is seen in two groups of patient t lymphocyte subset crowds' before and after treatment variation.
T lymphocyte subset crowd's variation before and after the table 6 liang group MODSE patient treatment
Can know that from The above results MODSE patient adds with contrast before and after the ad pro injection treatment, the CD3 among its t lymphocyte subset crowd, CD4, NK increase, and wherein compare obvious rising (P＜0.01) before CD3 and the treatment.Compare reduction before the comparing difference significantly (P＜0.05) before CD4, NK and the treatment, CD8 and treatment.
4.2 immunoglobulin in pilots is seen table 7 before and after two groups of patient treatments.
Immunoglobulin in pilots before and after the table 7 liang group MODSE patient treatment
Can know from last table: treatment group immunoglobulin G (IgG) and immunoglobulin A (IgA) level improve, and compare before the treatment, and difference has significance (P＜0.05).And treatment of control group front and back IgG and the equal no change of IgA.Two groups of equal no changes of IgM.
4.3 two groups of clinical efficacies are relatively seen table 8.
Table 8 liang group MODSE patient curative effect relatively
| Group | Produce effects | Effectively | Invalid | Effective percentage (%) |
| The treatment group | 9 | 10 | 3 | 86.4 |
| Matched group | 5 | 8 | 6 | 68.4 |
As illustrated above, treatment group total effective rate %, matched group total effective rate %, two groups relatively there were significant differences (P＜0.05), and the treatment group is superior to matched group.
5, conclusion
Multiple organ dysfunction had protective effect when above therapeutic outcome showed Aidi preparation to MODSE, and the immunocompetence of ability enhancing body, and patient's clinical symptoms and sign when improving MODSE explain that Aidi preparation has good curative effect and potential therapeutic value to MODSE.
Claims (6)
1. the purposes of Aidi preparation in the medicine of the old multiple organ dysfunction syndrome of preparation treatment; It is characterized in that: this Aidi preparation is by the Radix Ginseng of 25-100 weight portion; 0.5-5 the Mylabris of weight portion; The Radix Et Caulis Acanthopanacis Senticosi extract of the Radix Astragali of 50-200 weight portion and 100-200 weight portion is prepared from, and the purposes of this Aidi preparation in the medicine of the old multiple organ dysfunction syndrome of preparation treatment.
2. the purposes of Aidi preparation according to claim 1 in the medicine of the old multiple organ dysfunction syndrome of preparation treatment is characterized in that the weight proportion of this Aidi preparation crude drug is:
Radix Ginseng 30-70 part, Mylabris 1-2 part, Radix Astragali 75-125 part, Radix Et Caulis Acanthopanacis Senticosi 125-175 part.
3. the purposes of Aidi preparation according to claim 2 in the medicine of the old multiple organ dysfunction syndrome of preparation treatment is characterized in that the weight proportion of this Aidi preparation crude drug is:
50 parts of Radix Ginsengs, 1.5 parts of Mylabris, 100 parts of the Radixs Astragali, 150 parts of Radix Et Caulis Acanthopanacis Senticosis.
4. according to the purposes of the described Aidi preparation of claim 1 in the medicine of the old multiple organ dysfunction syndrome of preparation treatment, it is characterized in that: said Aidi preparation is injection, tablet, pill, capsule, granule, Emulsion, solution or suspending agent.
5. according to the purposes of the described Aidi preparation of claim 4 in the medicine of the old multiple organ dysfunction syndrome of preparation treatment, it is characterized in that: said Aidi preparation is an injection.
6. according to the purposes of the described Aidi preparation of claim 1 in the medicine of the old multiple organ dysfunction syndrome of preparation treatment, it is characterized in that: the route of administration of said Aidi preparation is oral, percutaneous, vein or intramuscular injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910102893XA CN102078367B (en) | 2009-11-26 | 2009-11-26 | Application of Aidi preparation in preparation of medicine for treating senile multiple organ dysfunction syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910102893XA CN102078367B (en) | 2009-11-26 | 2009-11-26 | Application of Aidi preparation in preparation of medicine for treating senile multiple organ dysfunction syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102078367A CN102078367A (en) | 2011-06-01 |
| CN102078367B true CN102078367B (en) | 2012-05-30 |
Family
ID=44084692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910102893XA Active CN102078367B (en) | 2009-11-26 | 2009-11-26 | Application of Aidi preparation in preparation of medicine for treating senile multiple organ dysfunction syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102078367B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103417607A (en) * | 2012-05-22 | 2013-12-04 | 贵州益佰制药股份有限公司 | Applications of traditional Aidi Chinese medicine composition and preparations thereof in preparing drugs for curing depression |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101306077A (en) * | 2008-06-04 | 2008-11-19 | 贵州益佰制药股份有限公司 | Chinese traditional injection preparation for treating cancer and its preparation method |
-
2009
- 2009-11-26 CN CN200910102893XA patent/CN102078367B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101306077A (en) * | 2008-06-04 | 2008-11-19 | 贵州益佰制药股份有限公司 | Chinese traditional injection preparation for treating cancer and its preparation method |
Non-Patent Citations (1)
| Title |
|---|
| 中华人民共和国卫生部药典委员会.艾迪注射液.《中华人民共和国卫生部药品标准中药成方制剂第二十册》.1998,85. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102078367A (en) | 2011-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102178800B (en) | Chinese medicine composition for treating rheumatoid arthritis and preparation method thereof | |
| CN101002906A (en) | Compounding traditional Chinese medicine, and its use | |
| CN102475835A (en) | Pharmaceutical composition for treating common cold or cough caused by common cold in children and preparation method thereof | |
| CN103816519A (en) | Spleen-strengthening dampness-removing traditional Chinese medicine composition and preparation method thereof | |
| WO2008061447A1 (en) | A medicine for treating eczema and process of ointment thereof | |
| CN101194982B (en) | Anti-depression traditional Chinese medicine composition and preparation method thereof | |
| CN102078367B (en) | Application of Aidi preparation in preparation of medicine for treating senile multiple organ dysfunction syndrome | |
| CN103989996B (en) | It is a kind of to treat Chinese medicine composition of diabetes and preparation method thereof | |
| CN103690768B (en) | Join stilbene soft capsule and preparation method thereof the tuber of dwarf lilyturf | |
| CN106310017B (en) | Traditional Chinese medicine granule for treating diffuse interstitial pulmonary fibrosis lung and kidney qi deficiency syndrome | |
| CN1272047C (en) | Medicine for invigorating liver and kidney to treat dryness of large intestine and constipation | |
| CN103705772B (en) | Chinese medicine composition that a kind of antiinflammatory protects the liver and preparation method thereof | |
| CN103933154B (en) | A kind of Chinese medicine composition treating goat and preparation method thereof | |
| CN102552767B (en) | Traditional Chinese medicine for treating kidney stone, preparation method and administration mode | |
| CN101564453A (en) | Medicine for treating chronic nonspecific ulcerative colitis and preparation method thereof | |
| CN105055967A (en) | Compound health care product having auxiliary blood sugar reducing function and preparation method | |
| CN104645246B (en) | A kind of pharmaceutical preparation depressed for Menopause | |
| CN103751583A (en) | Traditional Chinese medicine composition for being diuretic and protecting liver and preparation method of composition | |
| CN102935151B (en) | Medicine composition for protecting liver and lowering transaminase and preparation method and application thereof | |
| CN102397430B (en) | Cinobufotalin liver nourishing capsules | |
| CN101897752B (en) | Chinese medicinal composition and preparation method thereof | |
| CN105920436A (en) | Medicinal preparation for treating lung cancer and preparation method thereof | |
| CN101745011A (en) | Method for extracting ginseng, dwarf lilyturf tuber and schisandra chinensis and preparation thereof | |
| CN105687278A (en) | Pharmaceutical composition for treating middle and advanced stage lung cancer | |
| CN105232729A (en) | Preparation method and application of Sangdang total flavone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |